ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.59859
-0.02%
Brent Oil
83.945
0.42%
Bitcoin
66,305.80
0.05%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Mirati Therapeutics Inc (MRTX)

  7. Mirati Therapeutics Inc (MRTX) Noticias

MRTX

Mirati Therapeutics (MRTX)

Mirati Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MRTX
FechaHoraFuenteTítuloSímboloCompañía
14/02/202413:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRTXMirati Therapeutics Inc
02/02/202415:05Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MRTXMirati Therapeutics Inc
24/01/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MRTXMirati Therapeutics Inc
23/01/202419:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRTXMirati Therapeutics Inc
23/01/202408:31Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MRTXMirati Therapeutics Inc
23/01/202408:30Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:MRTXMirati Therapeutics Inc
23/01/202408:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:MRTXMirati Therapeutics Inc
23/01/202407:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRTXMirati Therapeutics Inc
10/01/202407:00PR Newswire (US)European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationNASDAQ:MRTXMirati Therapeutics Inc
27/12/202315:04Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRTXMirati Therapeutics Inc
06/12/202307:29Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:MRTXMirati Therapeutics Inc
10/11/202306:30PR Newswire (US)Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination ProcedureNASDAQ:MRTXMirati Therapeutics Inc
06/11/202307:00PR Newswire (US)Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:MRTXMirati Therapeutics Inc
06/11/202306:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRTXMirati Therapeutics Inc
03/11/202316:19PR Newswire (US)Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationNASDAQ:MRTXMirati Therapeutics Inc
02/11/202306:30Edgar (US Regulatory)Form DEFM14A - Definitive proxy statement relating to merger or acquisitionNASDAQ:MRTXMirati Therapeutics Inc
02/11/202306:30GlobeNewswire Inc.Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCNASDAQ:MRTXMirati Therapeutics Inc
23/10/202316:31Edgar (US Regulatory)Form PREM14A - Preliminary proxy statements relating to merger or acquisitionNASDAQ:MRTXMirati Therapeutics Inc
17/10/202315:00PR Newswire (US)Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)NASDAQ:MRTXMirati Therapeutics Inc
09/10/202309:30Dow Jones NewsTrending: Bristol Myers Squibb Buying Mirati TherapeuticsNASDAQ:MRTXMirati Therapeutics Inc
09/10/202306:33IH Market NewsMonday’s Wall Street Highlights: Exxon Mobil, Bristol-Myers, Disney, Lockheed Martin, and moreNASDAQ:MRTXMirati Therapeutics Inc
09/10/202305:26Dow Jones NewsMirati Shares Slip Premarket on Bristol Myers TakeoverNASDAQ:MRTXMirati Therapeutics Inc
08/10/202318:21KR Market News브리스톨-마이어스 스퀴브, 48억 달러에 미라티 인수NASDAQ:MRTXMirati Therapeutics Inc
08/10/202317:02Business WireBristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati TherapeuticsNASDAQ:MRTXMirati Therapeutics Inc
06/10/202301:56Dow Jones NewsSanofi Considering Acquisition of Mirati Therapeutics, Bloomberg ReportsNASDAQ:MRTXMirati Therapeutics Inc
05/10/202319:33KR Market News사노피, 항암제 제조사 미라티 인수 검토 – 외신NASDAQ:MRTXMirati Therapeutics Inc
05/10/202315:34Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MRTXMirati Therapeutics Inc
02/10/202315:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MRTXMirati Therapeutics Inc
27/09/202315:30PR Newswire (US)Mirati To Present Updated Clinical Data at ESMO Congress 2023NASDAQ:MRTXMirati Therapeutics Inc
09/09/202321:35PR Newswire (US)Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung CancerNASDAQ:MRTXMirati Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MRTX

Su Consulta Reciente

BTRX
BCPTBTC
LSE
79TI
Sg Issuer 28
BIT
I09264
Intesa Sanpaolo
COIN
ICCGBP
USOTC
CPWR
Ocean Thermal Energy (PK)
BOV
HOSI11
Fundo DE Investimento Im...
HITB
PVMUSDT
PRIVATEUM
NASDAQ
FTVTAX
Dow 30 Buywrite Portfoli...
NASDAQ
ALMAX
COIN
MCIGBP
BIT
P1SUH6
BNP Paribas Issuance
TG
AHYD
Amundi Luxembourg
TG
10AM
Amundi Index Global Agg ...
LSE
14VG
Sg Issuer 30
LSE
0HLQ
Bank Of New York Mellon
LSE
41OW
Sigma Fin.frn10
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados